Detailed narrative
Japan Regulatory Progress and Market Opportunity
BioCardia received a positive consultation record from Japan's PMDA, supporting the advancement of a Shonin pre-market regulatory submission for its cardiac cell therapy. The PMDA found positive outcomes from the CAR-D-AMP trials credible but requested additional details on guideline-directed medical therapy compliance and specific adverse events. BioCardia is preparing for submission next quarter, including completing the electronic trial master file and conducting GCP audits. The initial indication in Japan is expected to target approximately 20,000 patients, with approval anticipated 12 months post-submission. The company notes a competitor's cell therapy for the same indication was approved and reimbursed at $326,000 per treatment, underscoring the market need and potential for strong pricing.
US Regulatory Interactions for Cardi-Amp Heart Failure II and Helix Catheter
The FDA's Center for Biologics Evaluation and Research confirmed that the ongoing Cardi-Amp Heart Failure II trial may support premarket approval, viewing it as a confirmatory study. The agency had no safety or delivery concerns. BioCardia is actively enrolling patients, with four clinical sites recruiting and additional centers being onboarded. Separately, the FDA agreed on two pathways for marketing clearance of the Helix Transcendental Cardio Delivery Catheter System, raising no concerns on safety or performance. The preferred route is simultaneous approval with the cell therapy, but a de novo pathway is also suggested. The company is awaiting formal minutes from this meeting.
Financial Performance and Capital Management
BioCardia reported a decrease in total expenses by $0.4 million quarter-over-quarter to $1.6 million in Q2 FY26, and by $0.9 million to $3.9 million for the six months ended June 2026. This was primarily driven by a reduction in R&D expense due to the closeout of the CAR-D-AMP heart failure trial. The net loss for Q2 FY26 was $1.6 million, down from $2.0 million in Q2 FY25. The company raised approximately $4.9 million in net proceeds through its ATM facility at an average price of $1.22 per share, ending the quarter with $5.4 million in cash and cash equivalents, providing a runway into 2027 and maintaining NASDAQ compliance with $2.7 million in equity.
Business Development and Future Programs
BioCardia is engaged in active business development conversations in the Asia Pacific region for its cardiovascular therapeutics. The company expects any potential deal to include funding to advance Cardi-AMP for its second indication (chronic myocardial ischemia) and its allogeneic cardi-allo cell therapy for inflammatory heart failure. Business development for biotherapeutic delivery systems, particularly for gene-based therapy, is also active. The company is also working with CarTech to bring heart 3D fusion imaging to the clinic and market.
Cardi-Amp Heart Failure II Trial Enrollment and Endpoint Nuances
Enrollment in the Cardi-Amp Heart Failure II trial is progressing, with four active sites and additional patients expected to qualify and undergo procedures this month. The company is actively onboarding more centers to accelerate enrollment. Discussions with the FDA are ongoing regarding the outcome measures, specifically the third tier of the composite outcome, quality of life, which has received scientific criticism. BioCardia plans to streamline the trial to focus on the primary outcome measure and seek FDA guidance on handling this endpoint.